Bristol-myers Squibb Compnay

The Scripps Research Institute

Bristol-myers Squibb Holdings Ireland

Fukang Yang

Lawrence B Snyder

Denis R St Laurent

Omar D Lopez

Jeffrey Lee Romine

Jason T Goodrich

Makonen Belema

Van N Nguyen

Nicholas A Meanwell

Andrew Charles Good

Lawrence G Hamann

Edward H Ruediger

David R Langley

Alain Martel

Carol Bachand

Daniel H Deon

Clint A James

Rico Lavoie

Gan Wang

Michael H Serrano-Wu

Yuping Qiu

Ramesh Kakarla

Michael Frederick Parker

Andrew P Degnan

Xuejie Yang

Kevin W Gillman

Hong Huang

John E Macor

Sanjeev Gangwar

Qian Zhang

Dale L Boger

Joanne J Bronson

Soojin Kim

Qi Gao

Haiquan Fang

Min Gao

Guo Li

Matthew D Hill

John E Leet

Julie A Lemm

Donald R O'Boyle, Ii

Jayne Kapur

Darrell Maxwell

Belema Makonen

Ramesh Kakaria

Donald R Ii O'BOYLE

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.

Oxazolidinones as modulators of MGLUR5

seco-Cyclopropapyrroloindole compounds of formula (I) where Hal, R, R, and Rare as defined in the application, are potent anti-cancer agents that can be used in antibody-drug conjugates.

Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system. 

Oxazolidinones as modulators of mGluR5

The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.

The present disclosure generally relates to a crystalline form of methyl ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt. The present disclosure also generally relates to a pharmaceutical composition comprising a crystalline form, as well of methods of using a crystalline form in the treatment of Hepatitis C and methods for obtaining such crystalline form.

Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt

Growing community of inventors

Madison, CT, United States of America

Fukang Yang